Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$38.27 +5.3%	$39.55	$26.20 ▼ $63.50	$1.76B	1.43	565,052 shs	644,589 shs
BEAM Beam Therapeutics	$16.64 +3.9%	$18.74	$13.52 ▼ $35.25	$1.68B	2.22	2.52 million shs	2.39 million shs
DYN Dyne Therapeutics	$12.58 +2.9%	$10.23	$6.36 ▼ $46.81	$1.79B	1.08	3.04 million shs	2.30 million shs
ETON Eton Pharmaceuticals	$17.30 +1.2%	$15.00	$4.23 ▼ $21.48	$463.99M	1.13	352,437 shs	214,068 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	+2.63%	-6.25%	-3.06%	-20.86%
BEAM Beam Therapeutics	0.00%	-6.62%	-23.39%	-1.13%	-37.93%
DYN Dyne Therapeutics	0.00%	+1.62%	+26.43%	+7.61%	-72.96%
ETON Eton Pharmaceuticals	0.00%	+1.53%	+12.34%	-12.67%	+281.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGE Apogee Therapeutics	3.5567 of 5 stars	4.4	3.0	1.5	4.2	0.0
BEAM Beam Therapeutics	2.2347 of 5 stars	3.5	0.0	2.7	2.5	0.6
DYN Dyne Therapeutics	3.4201 of 5 stars	4.5	1.0	2.7	4.2	0.0
ETON Eton Pharmaceuticals	2.116 of 5 stars	3.5	1.0	2.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.86	Moderate Buy	$99.00	158.69% Upside
BEAM Beam Therapeutics	3.07	Buy	$48.45	191.19% Upside
DYN Dyne Therapeutics	3.00	Buy	$33.80	168.68% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	71.48% Upside

Current Analyst Ratings Breakdown

Latest ETON, BEAM, DYN, and APGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	APGE Apogee Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
8/6/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $21.00
8/6/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $13.00
7/31/2025	DYN Dyne Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$66.00 ➝ $36.00
7/29/2025	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $23.00
7/29/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$37.00 ➝ $31.00
7/29/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $38.00
7/21/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/15/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00
7/11/2025	DYN Dyne Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$15.92 per share	N/A
BEAM Beam Therapeutics	$63.52M	26.50	N/A	N/A	$8.86 per share	1.88
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.19 per share	N/A
ETON Eton Pharmaceuticals	$39.01M	11.89	N/A	N/A	$0.94 per share	18.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$182.15M	-$4.13	N/A	N/A	N/A	N/A	-34.65%	-32.76%	11/11/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	11/4/2025 (Estimated)
DYN Dyne Therapeutics	-$317.42M	-$3.86	N/A	N/A	N/A	N/A	-64.12%	-56.75%	11/11/2025 (Estimated)
ETON Eton Pharmaceuticals	-$3.82M	-$0.16	N/A	34.60	N/A	-7.10%	-0.73%	-0.22%	11/11/2025 (Estimated)

Latest ETON, BEAM, DYN, and APGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	APGE Apogee Therapeutics	-$1.03	-$1.13	-$0.10	-$1.13	N/A	N/A
8/7/2025	Q2 2025	ETON Eton Pharmaceuticals	-$0.01	-$0.10	-$0.09	-$0.10	$16.71 million	$18.93 million
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million
7/28/2025	Q2 2025	DYN Dyne Therapeutics	-$0.99	-$0.97	+$0.02	-$0.97	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	16.36	16.36
BEAM Beam Therapeutics	N/A	6.75	6.75
DYN Dyne Therapeutics	0.17	16.83	16.83
ETON Eton Pharmaceuticals	1.14	1.77	1.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
BEAM Beam Therapeutics	99.68%
DYN Dyne Therapeutics	96.68%
ETON Eton Pharmaceuticals	27.86%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	42.77%
BEAM Beam Therapeutics	3.50%
DYN Dyne Therapeutics	20.77%
ETON Eton Pharmaceuticals	14.89%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	46.11 million	26.39 million	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
DYN Dyne Therapeutics	100	142.26 million	112.72 million	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.83 million	Optionable

ETON, BEAM, DYN, and APGE Headlines

Recent News About These Companies

Insider Selling: Eton Pharmaceuticals (NASDAQ:ETON) CFO Sells 2,631 Shares of Stock

August 21, 2025 | insidertrades.com

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

August 20, 2025 | globenewswire.com

Craig-Hallum Sticks to Its Buy Rating for Eton Pharmaceuticals (ETON)

August 17, 2025 | theglobeandmail.com

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Bought by Connor Clark & Lunn Investment Management Ltd.

August 15, 2025 | marketbeat.com

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Sold by Informed Momentum Co LLC

August 14, 2025 | marketbeat.com

Eton Pharmaceuticals Reports Strong Q2 Growth Amid Challenges

August 13, 2025 | msn.com

Wall Street Zen Downgrades Eton Pharmaceuticals (NASDAQ:ETON) to Hold

August 10, 2025 | marketbeat.com

Eton targets $80M revenue run-rate in Q3 2025 as product launches accelerate

August 8, 2025 | msn.com

Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Eton (ETON) Q2 Revenue Jumps 108%

August 8, 2025 | aol.comA

Eton Pharmaceuticals: Growth At A Reasonable Price, Or Maybe Even Better With Options

August 8, 2025 | seekingalpha.com

Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates

August 7, 2025 | zacks.com

Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Eton Pharmaceuticals (ETON) to Release Quarterly Earnings on Thursday

August 1, 2025 | marketbeat.com

Neurocrine Biosciences Positioned For Growth And New Potential Blockbusters

July 31, 2025 | seekingalpha.com

Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

July 31, 2025 | zacks.com

Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

July 28, 2025 | globenewswire.com

Adrenal Crisis Market Analysis and Forecast Report 2025-2035 with Competitive Benchmarking of Eton Pharmaceuticals, Antares Pharma, and Pfizer

July 11, 2025 | finance.yahoo.com

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) - Seeking Alpha

July 9, 2025 | seekingalpha.com

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) - Morningstar

July 9, 2025 | morningstar.comM

Eton Pharmaceuticals Announces FDA Acceptance of NDA for ET-600 with Target Action Date of February 25, 2026 - Nasdaq

July 9, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ETON, BEAM, DYN, and APGE Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$38.27 +1.92 (+5.28%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$37.25 -1.02 (-2.67%)

As of 08/22/2025 07:50 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Beam Therapeutics NASDAQ:BEAM

$16.64 +0.63 (+3.94%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$16.71 +0.07 (+0.42%)

As of 08/22/2025 07:57 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Dyne Therapeutics NASDAQ:DYN

$12.58 +0.36 (+2.95%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$12.58 0.00 (0.00%)

As of 08/22/2025 05:55 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Eton Pharmaceuticals NASDAQ:ETON

$17.30 +0.21 (+1.23%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$17.26 -0.05 (-0.26%)

As of 08/22/2025 04:10 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time